Handa Pharmaceuticals Inc

As of June 30, 2026, Handa Pharmaceuticals Inc carries a market capitalization of 15.46B, placing it among publicly traded companies globally. Its enterprise value stands at 11.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Handa Pharmaceuticals Inc's next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, Handa Pharmaceuticals Inc has 162.53M shares outstanding.

As of June 30, 2026, Handa Pharmaceuticals Inc trades at a trailing price-to-earnings ratio of 31.39. The price-to-sales ratio is 12.71, and the price-to-book ratio stands at 3.08.

As of June 30, 2026, Handa Pharmaceuticals Inc trades at an EV/EBITDA multiple of 19.03 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 9.72 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 25.93 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Handa Pharmaceuticals Inc trades at an EV/FCF ratio of 18.49, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 11.77B versus a market cap of 15.46B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Handa Pharmaceuticals Inc maintains a current ratio of 8.97, meaning it holds 9.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.82, indicating moderate leverage, while an interest coverage ratio of 160.55 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Handa Pharmaceuticals Inc posted a return on equity (ROE) of 10.60, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.70 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.56, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 10.56, useful for judging operating efficiency across full business cycles. The company generates approximately 24.22M in revenue per employee across its workforce of 50.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Handa Pharmaceuticals Inc recorded 122.95M in income tax expense. That works out to an effective tax rate of 20.05, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 613.17M, leaving 490.22M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Handa Pharmaceuticals Inc's stock has gained approximately 8.59% over the past 52 weeks. The 50-day moving average sits at 113.55, while the 200-day moving average is 88.74.

Over the twelve months ended June 30, 2026, Handa Pharmaceuticals Inc generated 1.21B in revenue and converted that into 490.22M in net income, yielding earnings per share of 3.00. EBITDA reached 618.43M, while operating income came in at 453.87M.

As of June 30, 2026, Handa Pharmaceuticals Inc holds 3.73B in cash and equivalents against 41.03M in total debt, resulting in a net debt position of -1.50B. Total book value stands at 5.02B, with working capital of 3.71B providing operational flexibility.

Handa Pharmaceuticals Inc produced 662.01M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -28.72M in capital expenditures, free cash flow totaled 633.29M - equivalent to 3.91 per share.

Over the twelve months ended June 30, 2026, Handa Pharmaceuticals Inc posted a gross margin of 81.41, reflecting its pricing power and cost economics. The operating margin of 37.48 and net profit margin of 40.48 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Handa Pharmaceuticals Inc paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.07, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.59, meaning Handa Pharmaceuticals Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Handa Pharmaceuticals Inc's most recent stock split took place on June 8, 2023 with a 127:129 split ratio.

As of June 30, 2026, Handa Pharmaceuticals Inc has an Altman Z-Score of 18.27, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.